{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:43Z","timestamp":1793452123490,"version":"4.5.0"},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Emerging immunotherapeutic approaches have revolutionized the treatment of multiple malignancies. Immune checkpoint blockers (ICBs) have enabled never-before-seen success rates in durable tumor control and enhanced survival benefit in patients with advanced cancers. However, this effect is not universal, resulting in responder and nonresponder populations not only between, but also within solid tumor types. Although ICBs are thought to be most effective against tumors with more genetic mutations and higher antigen loads, this is not always the case for all cancers or for all patients within a cancer subtype. Furthermore, debilitating and sometimes deadly immune-related adverse events (irAEs) have resulted from aberrant activation of T-cell responses following immunotherapy. Thus, we must identify new ways to overcome resistance to ICB-based immunotherapies and limit irAEs. In fact, preclinical and clinical data have identified abnormalities in the tumor microenvironment (TME) that can thwart the efficacy of immunotherapies such as ICBs. Here, we will discuss how reprogramming various facets of the TME (blood vessels, myeloid cells, and regulatory T cells [Tregs]) may overcome TME-instigated resistance mechanisms to immunotherapy. We will discuss clinical applications of this strategic approach, including the recent successful phase III trial combining bevacizumab with atezolizumab and chemotherapy for metastatic nonsquamous non\u2013small cell lung cancer that led to rapid approval by the U.S. Food and Drug Administration of this regimen for first-line treatment. Given the accelerated testing and approval of ICBs combined with various targeted therapies in larger numbers of patients with cancer, we will discuss how these concepts and approaches can be incorporated into clinical practice to improve immunotherapy outcomes.<\/jats:p>","DOI":"10.1200\/edbk_237987","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T10:29:36Z","timestamp":1558088976000},"page":"165-174","source":"Crossref","is-referenced-by-count":176,"title":["Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies"],"prefix":"10.1200","author":[{"given":"Meenal","family":"Datta","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Coussens","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"From the Division of Cancer Immunology, Research Institute, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Japan, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"bibr1-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"bibr2-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8"},{"key":"bibr3-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006"},{"key":"bibr4-EDBK_237987","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"Palucka AK","year":"2016","journal-title":"Cell"},{"key":"bibr5-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.015"},{"key":"bibr6-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"bibr7-EDBK_237987","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"Chauhan VP","year":"2013","journal-title":"Nat Commun"},{"key":"bibr8-EDBK_237987","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","volume":"6","author":"Incio J","year":"2016","journal-title":"Cancer Discov"},{"key":"bibr9-EDBK_237987","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-17-0256","volume":"23","author":"Liu H","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bibr10-EDBK_237987","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","volume":"116","author":"Zhao Y","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"bibr11-EDBK_237987","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","volume":"81","author":"Martin JD","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"bibr12-EDBK_237987","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2017.04.015","volume":"46","author":"De Palma M","year":"2017","journal-title":"Immunity"},{"key":"bibr13-EDBK_237987","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"Pinter M","year":"2017","journal-title":"Sci Transl Med"},{"key":"bibr14-EDBK_237987","first-page":"201815515","author":"Chen IX","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"bibr15-EDBK_237987","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","volume":"29","author":"DeNardo DG","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"bibr16-EDBK_237987","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"De Palma M","year":"2013","journal-title":"Cancer Cell"},{"key":"bibr17-EDBK_237987","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-018-0435-6","volume":"6","author":"Saung MT","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bibr18-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00202"},{"key":"bibr19-EDBK_237987","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.13625","volume":"1417","author":"Shitara K","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"bibr20-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1525349113"},{"key":"bibr21-EDBK_237987","first-page":"51","volume":"305","author":"Sakaguchi S","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"bibr22-EDBK_237987","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","volume":"14","author":"Liston A","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"bibr23-EDBK_237987","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2014.00333","volume":"5","author":"Gratz IK","year":"2014","journal-title":"Front Immunol"},{"key":"bibr24-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.12.005"},{"key":"bibr25-EDBK_237987","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1073\/pnas.1720447115","volume":"115","author":"Yates K","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"bibr26-EDBK_237987","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41590-018-0051-0","volume":"19","author":"Zemmour D","year":"2018","journal-title":"Nat Immunol"},{"key":"bibr27-EDBK_237987","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1073\/pnas.1604765113","volume":"113","author":"Nakagawa H","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"bibr28-EDBK_237987","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"Overacre-Delgoffe AE","year":"2017","journal-title":"Cell"},{"key":"bibr29-EDBK_237987","author":"Togashi Y","journal-title":"Nat Rev Clin Oncol"},{"key":"bibr30-EDBK_237987","volume":"36","author":"Togashi Y","year":"2018","journal-title":"J Clin Oncol"},{"key":"bibr31-EDBK_237987","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"O\u2019Rourke DM","year":"2017","journal-title":"Sci Transl Med"},{"key":"bibr32-EDBK_237987","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1126\/science.aad0616","volume":"350","author":"Kim HJ","year":"2015","journal-title":"Science"},{"key":"bibr33-EDBK_237987","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nri3464","volume":"13","author":"Sakaguchi S","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"bibr34-EDBK_237987","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/imr.12173","volume":"259","author":"Sawant DV","year":"2014","journal-title":"Immunol Rev"},{"key":"bibr35-EDBK_237987","first-page":"134ra62","volume":"4","author":"Rech AJ","year":"2012","journal-title":"Sci Transl Med"},{"key":"bibr36-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900986"},{"key":"bibr37-EDBK_237987","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4049\/jimmunol.1403039","volume":"196","author":"Akhmetzyanova I","year":"2016","journal-title":"J Immunol"},{"key":"bibr38-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354"},{"key":"bibr39-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0403-1"},{"key":"bibr40-EDBK_237987","volume":"36","author":"Stein S","year":"2018","journal-title":"J Clin Oncol"},{"key":"bibr41-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0"},{"key":"bibr42-EDBK_237987","author":"Rini BI","journal-title":"N Engl J Med"},{"key":"bibr43-EDBK_237987","author":"Motzer RJ","journal-title":"N Engl J Med"},{"key":"bibr44-EDBK_237987","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624"},{"key":"bibr45-EDBK_237987","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","volume":"4","author":"Wu X","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bibr46-EDBK_237987","doi-asserted-by":"crossref","first-page":"e1440930","DOI":"10.1080\/2162402X.2018.1440930","volume":"7","author":"Wu X","year":"2018","journal-title":"OncoImmunology"},{"key":"bibr47-EDBK_237987","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","volume":"5","author":"Wu X","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK_237987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:39:04Z","timestamp":1653799144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_237987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":47,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1200\/EDBK_237987"],"URL":"https:\/\/doi.org\/10.1200\/edbk_237987","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}